Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A recent study of people in British Columbia found, however, that people who inject drugs had lower cure rates.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
Those who took the drug, which is included in Zepatier (grazoprevir/elbasvir), had a low rate of liver cancer during the following years.
That’s according to an analysis of four large health systems from around the United States.
Researchers pooled data from numerous real-world cohorts from various nations.
Nearly all those treated in a recent trial were cured.
A considerable proportion of a group of people receiving HIV care had signs of the disease, but only a small group was diagnosed.
People without hep C received kidney, liver or heart transplants from HCV-positive donors and then were treated for the virus.
This finding suggests sex between men and the sharing of drug-sniffing equipment are possible routes of transmission.
In a recent trial, Gilead’s regimen was highly successful in a group that included those with and without HIV coinfection.
Viking Therapeutics’ investigational drug is called VK2809.
Taking Vemlidy rather than Viread as prophylaxis against hepatitis B is tied to better markers of kidney and bone health.
The study population included those with all hepatitis C genotypes—except genotype 3.
This is according to a Phase IIb trial of the medication.
The generally false presumption that they won’t adhere to the regimen is often used to deny coverage for hep C medications.
Having a low CD4 count was also associated with the liver condition in a recent small study.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.